TrialSignal
Clinical trial intelligence report
Efficacy and Safety of Pegmolesatide in Dialysis Chronic Kidney Disease (CKD) Patients With Anemia Treated With Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI): a Multi-center, Prospective, Open-label, Randomized Parallel Controlled Trial
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT07136792
Status
RECRUITING
Phase
Recruiting
Sponsor
Guangdong Provincial People's Hospital
Executive brief
Investment-Ready Snapshot
This clinical trial evaluates the efficacy and safety of Pegmolesatide, a long-acting erythropoiesis-stimulating agent, in dialysis patients with renal anemia previously treated with HIF-PHIs. The study aims to address the clinical need for effective switching options and establish dosing standards.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT07136792
Indication
Renal Anemia of Chronic Kidney Disease
Modality
small molecule
Target
Pegmolesatide for renal anemia in dialysis patients
Intervention
Pegmolesatide 2mg SC, Pegmolesatide 4mg SC, Pegmolesatide 4mg SC, Pegmolesatide 6mg SC
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.